[A22-115] Ravulizumab (generalized myasthenia gravis) – Benefit assessment according to § 35a SGB V

Last updated 14.04.2023

Project no.:
A22-115

Commission:
Commission awarded on 21.10.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Immune system and infections

Indication:

Adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

Result of dossier assessment:
  • Adults who are still eligible for standard treatment: added benefit not proven
  • Adults with refractory disease: added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-02-01.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form